ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
1.830
-0.030 (-1.61%)
At close: Apr 28, 2026, 4:00 PM EDT
1.840
+0.010 (0.55%)
After-hours: Apr 28, 2026, 7:24 PM EDT
Company Description
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Boulevard, Suite 250 Winston-Salem, North Carolina 27103 United States | |
| Phone | 336 999 7019 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| CUSIP Number | 74291D104 |
| ISIN Number | US74291D1046 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Secretary |
| Dr. Ulrich Ernst Ph.D. | Executive Vice President of Science and Technology |
| Richard Williams | Chief Information Officer |
| Carla Poulson | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Dr. Emily Butler Ph.D. | Senior Vice President of Biometric |
| Gregory P. Madison | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2026 | ARS | Filing |
| Apr 17, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 18, 2026 | 10-K | Annual Report |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Feb 2, 2026 | 8-K | Current Report |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 18, 2025 | EFFECT | Notice of Effectiveness |